Isomorphic Labs Secures $600 Million Funding Led By Thrive Capital With Partners Eli Lilly And Novartis

Isomorphic Labs, the AI drug discovery platform spun out of DeepMind in 2021, has raised $600 million in its first external funding round led by Thrive Capital, with participation from GV and Alphabet. Founded by DeepMind co-founder Demis Hassabis, the company leverages AI models like AlphaFold to accelerate drug design. The funding will support further development and hiring of top research talent. Isomorphic Labs has secured partnerships with Eli Lilly and Novartis, potentially generating up to $3 billion in milestone payments. INVESTORS: Thrive Capital, GV & Alphabet AMOUNT: $600,000,000 HQ: #London #UnitedKingdom #VentureCapital #IsomorphicLabs #ThriveCapital #GV #Alphabet #DemisHassabis #TradedVC